ADARx Pharmaceuticals, Inc.
NASDAQ:ADRXBiotechnology
+$0.13 today
- Market cap
- $1.42B
- Beta
- 0.00
Volume 0.65M
Average 1.06M
ADRX Other Non-Cash Items
Other non-cash adjustments that reconcile net income to operating cash flow.
Other Non-Cash Items history
Currency unavailable · from the cash flow
No Other Non-Cash Items data reported for this period type.
Other Non-Cash Items vs competitors
How ADRX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $179.4M USD | +22894.9% | -19.7% | 224.9% | |
| LTM Mar 2026 | $70.22M USD | — | — | 7620.1% | |
| LTM Mar 2026 | $13.59M USD | +536.4% | — | — | |
| LTM Mar 2026 | $9.75M USD | +360.5% | +6.0% | 30.4% | |
| LTM Mar 2026 | $9.43M USD | — | +1176.7% | 13.1% | |
| LTM Mar 2026 | $8.21M USD | -29.9% | -19.4% | 203.5% | |
| LTM Mar 2026 | €3.3M EUR | +368.6% | — | 24.5% | |
| LTM Mar 2026 | $2.66M USD | +505.4% | -9.4% | 5.9% | |
| FY2025 | $712K USD | — | — | 3.8% | |
ADRXADARx Pharmaceuticals, Inc. | — | — | — | — | — |
| Peer median (excluding ADRX) | — | +437.0% | -9.4% | 27.5% | |
Competitors are the stored peer set for ADRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
ADARx Pharmaceuticals, Inc.
NASDAQ:ADRX
Intrinsic Alpha fair value
Locked
Current Price
$12.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.